EA202090291A2 - Производные бипиразола в качестве ингибиторов jak - Google Patents
Производные бипиразола в качестве ингибиторов jakInfo
- Publication number
- EA202090291A2 EA202090291A2 EA202090291A EA202090291A EA202090291A2 EA 202090291 A2 EA202090291 A2 EA 202090291A2 EA 202090291 A EA202090291 A EA 202090291A EA 202090291 A EA202090291 A EA 202090291A EA 202090291 A2 EA202090291 A2 EA 202090291A2
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- bipirazole
- derivatives
- jak inhibitors
- diseases
- jak
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Virology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
Abstract
В изобретении предложены соединения формулы Iили их фармацевтически приемлемые соли, а также их композиции и способы их применения, которые ингибируют активность Янус-киназы (JAK) и подходят для применения для лечения заболеваний, связанных с активностью JAK, включая, например, воспалительные заболевания, аутоиммунные заболевания, раковые заболевания и другие заболевания.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361824683P | 2013-05-17 | 2013-05-17 |
Publications (3)
Publication Number | Publication Date |
---|---|
EA202090291A2 true EA202090291A2 (ru) | 2020-05-31 |
EA202090291A3 EA202090291A3 (ru) | 2020-06-30 |
EA039660B1 EA039660B1 (ru) | 2022-02-24 |
Family
ID=50983151
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201592199A EA036448B1 (ru) | 2013-05-17 | 2014-05-16 | Производные бипиразола в качестве ингибиторов jak |
EA202090291A EA039660B1 (ru) | 2013-05-17 | 2014-05-16 | Твердая форма производного бипиразола |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201592199A EA036448B1 (ru) | 2013-05-17 | 2014-05-16 | Производные бипиразола в качестве ингибиторов jak |
Country Status (35)
Country | Link |
---|---|
US (7) | US9382231B2 (ru) |
EP (5) | EP4275756A3 (ru) |
JP (4) | JP6415543B2 (ru) |
KR (4) | KR102442747B1 (ru) |
CN (2) | CN107698569B (ru) |
AR (2) | AR096330A1 (ru) |
AU (5) | AU2014265279B2 (ru) |
BR (1) | BR112015028501B8 (ru) |
CA (1) | CA2911536C (ru) |
CL (1) | CL2015003355A1 (ru) |
CR (2) | CR20190156A (ru) |
CY (3) | CY1119105T1 (ru) |
DK (3) | DK3786162T3 (ru) |
EA (2) | EA036448B1 (ru) |
ES (4) | ES2960731T3 (ru) |
FI (1) | FI3786162T3 (ru) |
HK (2) | HK1221466A1 (ru) |
HR (4) | HRP20231048T1 (ru) |
HU (4) | HUE053122T2 (ru) |
IL (4) | IL242453B (ru) |
LT (4) | LT3527263T (ru) |
ME (2) | ME03355B (ru) |
MX (2) | MX2015015738A (ru) |
MY (1) | MY174788A (ru) |
PE (2) | PE20200527A1 (ru) |
PH (2) | PH12015502563A1 (ru) |
PL (4) | PL3231801T3 (ru) |
PT (4) | PT2997023T (ru) |
RS (4) | RS56012B1 (ru) |
SG (2) | SG10201709469SA (ru) |
SI (4) | SI2997023T1 (ru) |
TR (1) | TR201905814T4 (ru) |
TW (2) | TWI664176B (ru) |
UA (1) | UA117830C2 (ru) |
WO (1) | WO2014186706A1 (ru) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE030235T2 (en) | 2005-12-13 | 2017-04-28 | Incyte Holdings Corp | Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors |
EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
EA020494B1 (ru) | 2009-05-22 | 2014-11-28 | Инсайт Корпорейшн | 3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ]ОКТАН- ИЛИ ГЕПТАННИТРИЛ КАК JAK-ИНГИБИТОРЫ |
AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
NZ597050A (en) | 2009-06-29 | 2014-02-28 | Incyte Corp | Pyrimidinones as pi3k inhibitors |
AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
MX347851B (es) | 2010-03-10 | 2017-05-16 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
EP3087972A1 (en) | 2010-05-21 | 2016-11-02 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
SG190839A1 (en) | 2010-11-19 | 2013-07-31 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
AR084366A1 (es) | 2010-12-20 | 2013-05-08 | Incyte Corp | N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k |
AR086983A1 (es) | 2011-06-20 | 2014-02-05 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
BR122019020716B1 (pt) | 2011-09-02 | 2021-02-17 | Incyte Holdings Corporation | heterociclilaminas como inibidores de pi3k e composição farmacêutica que as compreende |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
NZ707495A (en) | 2012-11-01 | 2019-01-25 | Incyte Holdings Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
KR20220162825A (ko) | 2012-11-15 | 2022-12-08 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
AU2014225938B2 (en) | 2013-03-06 | 2018-07-19 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
DK3786162T3 (da) | 2013-05-17 | 2023-10-09 | Incyte Holdings Corp | Bipyrazolderivater som jak-inhibitorer |
KR20160045081A (ko) | 2013-08-07 | 2016-04-26 | 인사이트 코포레이션 | Jak1 억제제용 지속 방출 복용 형태 |
ES2688553T3 (es) * | 2014-02-28 | 2018-11-05 | Incyte Corporation | Inhibidores de JAK1 para el tratamiento de síndromes mielodisplásicos |
US10064866B2 (en) | 2014-04-08 | 2018-09-04 | Incyte Corporation | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors |
TW201625643A (zh) | 2014-04-30 | 2016-07-16 | 英塞特公司 | 製備jak1抑制劑之方法及其新形式 |
WO2015184305A1 (en) * | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
MD3262046T2 (ro) | 2015-02-27 | 2021-03-31 | Incyte Corp | Săruri de inhibitori ai PI3K și procedee pentru prepararea lor |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
US11052094B2 (en) * | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
AR106595A1 (es) | 2015-11-06 | 2018-01-31 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
ES2833955T3 (es) | 2016-01-05 | 2021-06-16 | Incyte Corp | Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma |
WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
CN107759623B (zh) * | 2016-08-23 | 2020-08-14 | 苏州旺山旺水生物医药有限公司 | Jak抑制剂的中间体及其制备方法 |
CN109890817B (zh) * | 2016-09-06 | 2022-06-17 | 豪夫迈·罗氏有限公司 | 8-(氮杂环丁烷-1-基)-[1,2,4]三唑并[1,5-a]吡啶基化合物、其组合物和应用方法 |
EP4006034A1 (en) | 2017-10-18 | 2022-06-01 | Incyte Corporation | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors |
TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
TWI797242B (zh) | 2018-01-30 | 2023-04-01 | 美商英塞特公司 | 製備jak抑制劑之方法及中間物 |
AU2019221667A1 (en) | 2018-02-16 | 2020-10-01 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of cytokine-related disorders |
MA52655A (fr) | 2018-03-30 | 2021-02-17 | Incyte Corp | Biomarqueurs pour maladie cutanée inflammatoire |
MX2022012285A (es) * | 2018-03-30 | 2023-08-15 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
WO2019200030A1 (en) * | 2018-04-13 | 2019-10-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
CN108484468A (zh) * | 2018-05-11 | 2018-09-04 | 南京大学 | 芳基氮杂环丁烷类化合物的制备方法 |
MA53561A (fr) | 2018-09-05 | 2022-05-11 | Incyte Corp | Formes cristallines d'un inhibiteur de phosphoinositide 3-kinase (pi3k) |
JP7431845B2 (ja) | 2018-10-31 | 2024-02-15 | インサイト・コーポレイション | 血液疾患の治療のための併用療法 |
CA3123596A1 (en) | 2018-12-19 | 2020-06-25 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
EP3934651A1 (en) | 2019-03-05 | 2022-01-12 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
WO2020191041A2 (en) | 2019-03-19 | 2020-09-24 | Incyte Corporation | Biomarkers for vitiligo |
EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
JP2022551649A (ja) | 2019-10-10 | 2022-12-12 | インサイト・コーポレイション | 移植片対宿主病のバイオマーカー |
US20210123931A1 (en) | 2019-10-10 | 2021-04-29 | Incyte Corporation | Biomarkers for graft-versus-host disease |
JP2023506118A (ja) * | 2019-10-16 | 2023-02-15 | インサイト・コーポレイション | 皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用 |
US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
BR112022024632A2 (pt) | 2020-06-02 | 2023-02-28 | Incyte Corp | Processos para preparar um inibidor de jak1 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
MX2023002035A (es) | 2020-08-18 | 2023-06-12 | Incyte Corp | Proceso e intermediarios para preparar un inhibidor de cinasa janus 1 (jak1). |
KR20230096973A (ko) | 2020-08-18 | 2023-06-30 | 인사이트 코포레이션 | Jak 저해제를 제조하기 위한 방법 및 중간체 |
CN112159394B (zh) * | 2020-10-09 | 2021-10-22 | 嘉兴特科罗生物科技有限公司 | 一种作为jak激酶抑制剂的小分子化合物及其用途 |
MX2023006638A (es) | 2020-12-04 | 2023-08-22 | Incyte Corp | Inhibidor de la cinasa janus (jak) con un análogo de la vitamina d para el tratamiento de enfermedades de la piel. |
TW202237089A (zh) | 2020-12-08 | 2022-10-01 | 美商英塞特公司 | 用於治療白斑病之jak1途徑抑制劑 |
CN112933095A (zh) * | 2020-12-29 | 2021-06-11 | 上海岸阔医药科技有限公司 | 预防或治疗egfr功能异常相关的副作用的方法 |
US11918581B2 (en) | 2021-01-11 | 2024-03-05 | Incyte Corporation | Combination therapy comprising JAK pathway inhibitor and rock inhibitor |
CN117693339A (zh) | 2021-05-03 | 2024-03-12 | 因赛特公司 | 用于治疗结节性痒疹的jak1途径抑制剂 |
WO2024030600A1 (en) | 2022-08-05 | 2024-02-08 | Incyte Corporation | Treatment of urticaria using jak inhibitors |
CN117186078A (zh) * | 2023-11-06 | 2023-12-08 | 药康众拓(北京)医药科技有限公司 | 氘代氮杂环丁烷类jak抑制剂药物及用途 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5646749A (en) * | 1979-09-26 | 1981-04-28 | Mitsui Toatsu Chemicals | Protective sheet for surface |
JPS60106847U (ja) | 1983-12-27 | 1985-07-20 | 富士重工業株式会社 | 室外後写鏡 |
JP2650681B2 (ja) | 1987-07-10 | 1997-09-03 | 株式会社ブリヂストン | 空気ばね |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
JP4516690B2 (ja) | 1998-08-11 | 2010-08-04 | ノバルティス アーゲー | 血管形成阻害活性を有するイソキノリン誘導体 |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
PT1294358E (pt) | 2000-06-28 | 2004-12-31 | Smithkline Beecham Plc | Processo de moagem por via humida |
EP1436291B1 (en) | 2001-09-19 | 2009-01-14 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
CN1582150B (zh) | 2001-10-30 | 2011-09-07 | 诺瓦提斯公司 | 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物 |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
AU2005309019A1 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors |
HUE030235T2 (en) | 2005-12-13 | 2017-04-28 | Incyte Holdings Corp | Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
NZ585139A (en) * | 2007-11-16 | 2012-05-25 | Incyte Corp | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as jak inhibitors |
ES2602577T3 (es) * | 2008-03-11 | 2017-02-21 | Incyte Holdings Corporation | Derivados de azetidina y ciclobutano como inhibidores de JAK |
CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
EA020494B1 (ru) | 2009-05-22 | 2014-11-28 | Инсайт Корпорейшн | 3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ]ОКТАН- ИЛИ ГЕПТАННИТРИЛ КАК JAK-ИНГИБИТОРЫ |
AR078012A1 (es) * | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
WO2011044481A1 (en) | 2009-10-09 | 2011-04-14 | Incyte Corporation | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
BR112012020693B1 (pt) | 2010-02-18 | 2020-05-12 | Incyte Holdings Corporation | Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende |
MX347851B (es) | 2010-03-10 | 2017-05-16 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
WO2011130146A1 (en) * | 2010-04-14 | 2011-10-20 | Array Biopharma Inc. | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases |
EP3087972A1 (en) | 2010-05-21 | 2016-11-02 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
EP2640725B1 (en) | 2010-11-19 | 2015-01-07 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
SG190839A1 (en) | 2010-11-19 | 2013-07-31 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
CA2820109C (en) | 2010-12-10 | 2018-01-09 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
SG192910A1 (en) | 2011-02-24 | 2013-09-30 | Massachusetts Inst Technology | ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER |
AR086983A1 (es) * | 2011-06-20 | 2014-02-05 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) * | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
US9328099B2 (en) | 2011-09-22 | 2016-05-03 | Merck Sharp & Dohme Corp. | Cyanomethylpyrazole carboxamides as janus kinase inhibitors |
AR091079A1 (es) * | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
NZ707495A (en) | 2012-11-01 | 2019-01-25 | Incyte Holdings Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
KR20220162825A (ko) | 2012-11-15 | 2022-12-08 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
AU2014225938B2 (en) | 2013-03-06 | 2018-07-19 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
DK3786162T3 (da) | 2013-05-17 | 2023-10-09 | Incyte Holdings Corp | Bipyrazolderivater som jak-inhibitorer |
EA201592126A1 (ru) | 2013-05-17 | 2016-05-31 | Ф. Хоффманн-Ля Рош Аг | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
KR20160045081A (ko) | 2013-08-07 | 2016-04-26 | 인사이트 코포레이션 | Jak1 억제제용 지속 방출 복용 형태 |
ES2688553T3 (es) | 2014-02-28 | 2018-11-05 | Incyte Corporation | Inhibidores de JAK1 para el tratamiento de síndromes mielodisplásicos |
TW201625643A (zh) | 2014-04-30 | 2016-07-16 | 英塞特公司 | 製備jak1抑制劑之方法及其新形式 |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
DK3233843T3 (da) | 2014-12-16 | 2019-11-18 | Novartis Ag | Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere |
BR112022024632A2 (pt) | 2020-06-02 | 2023-02-28 | Incyte Corp | Processos para preparar um inibidor de jak1 |
-
2014
- 2014-05-16 DK DK20201593.9T patent/DK3786162T3/da active
- 2014-05-16 EP EP23185889.5A patent/EP4275756A3/en active Pending
- 2014-05-16 EA EA201592199A patent/EA036448B1/ru unknown
- 2014-05-16 ES ES20201593T patent/ES2960731T3/es active Active
- 2014-05-16 EA EA202090291A patent/EA039660B1/ru unknown
- 2014-05-16 JP JP2016514126A patent/JP6415543B2/ja active Active
- 2014-05-16 LT LTEP18215671.1T patent/LT3527263T/lt unknown
- 2014-05-16 DK DK17158350.3T patent/DK3231801T3/en active
- 2014-05-16 PE PE2020000001A patent/PE20200527A1/es unknown
- 2014-05-16 CR CR20190156A patent/CR20190156A/es unknown
- 2014-05-16 EP EP18215671.1A patent/EP3527263B1/en active Active
- 2014-05-16 KR KR1020217030190A patent/KR102442747B1/ko active IP Right Grant
- 2014-05-16 AU AU2014265279A patent/AU2014265279B2/en active Active
- 2014-05-16 PL PL17158350T patent/PL3231801T3/pl unknown
- 2014-05-16 TW TW103117400A patent/TWI664176B/zh active
- 2014-05-16 PL PL14732705T patent/PL2997023T3/pl unknown
- 2014-05-16 SI SI201430239A patent/SI2997023T1/sl unknown
- 2014-05-16 RS RS20170526A patent/RS56012B1/sr unknown
- 2014-05-16 SI SI201431754T patent/SI3527263T1/sl unknown
- 2014-05-16 HU HUE18215671A patent/HUE053122T2/hu unknown
- 2014-05-16 HU HUE20201593A patent/HUE063817T2/hu unknown
- 2014-05-16 PT PT147327050T patent/PT2997023T/pt unknown
- 2014-05-16 BR BR112015028501A patent/BR112015028501B8/pt active IP Right Grant
- 2014-05-16 TR TR2019/05814T patent/TR201905814T4/tr unknown
- 2014-05-16 FI FIEP20201593.9T patent/FI3786162T3/fi active
- 2014-05-16 ES ES18215671T patent/ES2845210T3/es active Active
- 2014-05-16 CN CN201711000293.3A patent/CN107698569B/zh active Active
- 2014-05-16 MX MX2015015738A patent/MX2015015738A/es active IP Right Grant
- 2014-05-16 RS RS20230782A patent/RS64591B1/sr unknown
- 2014-05-16 SG SG10201709469SA patent/SG10201709469SA/en unknown
- 2014-05-16 KR KR1020157035750A patent/KR102341908B1/ko active IP Right Grant
- 2014-05-16 LT LTEP20201593.9T patent/LT3786162T/lt unknown
- 2014-05-16 RS RS20190315A patent/RS58743B1/sr unknown
- 2014-05-16 MY MYPI2015002767A patent/MY174788A/en unknown
- 2014-05-16 SG SG11201509180WA patent/SG11201509180WA/en unknown
- 2014-05-16 LT LTEP14732705.0T patent/LT2997023T/lt unknown
- 2014-05-16 EP EP20201593.9A patent/EP3786162B1/en active Active
- 2014-05-16 SI SI201431118T patent/SI3231801T1/sl unknown
- 2014-05-16 WO PCT/US2014/038388 patent/WO2014186706A1/en active Application Filing
- 2014-05-16 CN CN201480032106.8A patent/CN105452239B/zh active Active
- 2014-05-16 PT PT182156711T patent/PT3527263T/pt unknown
- 2014-05-16 UA UAA201512465A patent/UA117830C2/uk unknown
- 2014-05-16 LT LTEP17158350.3T patent/LT3231801T/lt unknown
- 2014-05-16 PT PT17158350T patent/PT3231801T/pt unknown
- 2014-05-16 ES ES17158350T patent/ES2720073T3/es active Active
- 2014-05-16 PT PT202015939T patent/PT3786162T/pt unknown
- 2014-05-16 CA CA2911536A patent/CA2911536C/en active Active
- 2014-05-16 KR KR1020247014111A patent/KR20240063187A/ko active Search and Examination
- 2014-05-16 HU HUE14732705A patent/HUE033587T2/hu unknown
- 2014-05-16 TW TW108103947A patent/TWI719401B/zh active
- 2014-05-16 PL PL20201593.9T patent/PL3786162T3/pl unknown
- 2014-05-16 SI SI201432046T patent/SI3786162T1/sl unknown
- 2014-05-16 PE PE2015002406A patent/PE20160126A1/es unknown
- 2014-05-16 PL PL18215671T patent/PL3527263T3/pl unknown
- 2014-05-16 HU HUE17158350A patent/HUE043573T2/hu unknown
- 2014-05-16 ES ES14732705.0T patent/ES2626793T3/es active Active
- 2014-05-16 HR HRP20231048TT patent/HRP20231048T1/hr unknown
- 2014-05-16 EP EP17158350.3A patent/EP3231801B1/en active Active
- 2014-05-16 RS RS20210074A patent/RS61482B1/sr unknown
- 2014-05-16 MX MX2020004506A patent/MX2020004506A/es unknown
- 2014-05-16 DK DK18215671.1T patent/DK3527263T3/da active
- 2014-05-16 US US14/279,929 patent/US9382231B2/en active Active
- 2014-05-16 ME MEP-2019-79A patent/ME03355B/me unknown
- 2014-05-16 ME MEP-2017-116A patent/ME02763B/me unknown
- 2014-05-16 KR KR1020227030853A patent/KR102663357B1/ko active IP Right Grant
- 2014-05-16 AR ARP140101971A patent/AR096330A1/es active IP Right Grant
- 2014-05-16 EP EP14732705.0A patent/EP2997023B9/en active Active
-
2015
- 2015-11-04 IL IL24245315A patent/IL242453B/en active IP Right Grant
- 2015-11-12 PH PH12015502563A patent/PH12015502563A1/en unknown
- 2015-11-13 CL CL2015003355A patent/CL2015003355A1/es unknown
- 2015-12-03 CR CR20150633A patent/CR20150633A/es unknown
-
2016
- 2016-06-20 US US15/187,296 patent/US9926301B2/en active Active
- 2016-08-11 HK HK16109588.1A patent/HK1221466A1/zh unknown
-
2017
- 2017-05-29 HR HRP20170795TT patent/HRP20170795T1/hr unknown
- 2017-06-08 CY CY20171100610T patent/CY1119105T1/el unknown
-
2018
- 2018-02-15 US US15/897,598 patent/US10435392B2/en active Active
- 2018-04-18 HK HK18105021.2A patent/HK1245769B/zh unknown
- 2018-08-31 AU AU2018223058A patent/AU2018223058B2/en active Active
- 2018-10-02 JP JP2018187613A patent/JP6775560B2/ja active Active
- 2018-10-02 PH PH12018502125A patent/PH12018502125A1/en unknown
-
2019
- 2019-01-22 IL IL264409A patent/IL264409B/en active IP Right Grant
- 2019-04-16 HR HRP20190713TT patent/HRP20190713T1/hr unknown
- 2019-05-10 CY CY20191100510T patent/CY1121763T1/el unknown
- 2019-08-29 US US16/555,620 patent/US11001571B2/en active Active
-
2020
- 2020-02-17 AR ARP200100433A patent/AR118120A2/es unknown
- 2020-03-19 AU AU2020202000A patent/AU2020202000B2/en active Active
- 2020-10-06 JP JP2020168950A patent/JP7126741B2/ja active Active
-
2021
- 2021-01-22 CY CY20211100050T patent/CY1123756T1/el unknown
- 2021-01-22 HR HRP20210119TT patent/HRP20210119T1/hr unknown
- 2021-04-13 US US17/229,397 patent/US11591318B2/en active Active
- 2021-04-26 IL IL282644A patent/IL282644B/en unknown
- 2021-04-29 AU AU2021202685A patent/AU2021202685B2/en active Active
- 2021-10-17 IL IL287313A patent/IL287313B/en unknown
-
2022
- 2022-08-10 JP JP2022128042A patent/JP2022163162A/ja active Pending
- 2022-10-31 AU AU2022263454A patent/AU2022263454B2/en active Active
-
2023
- 2023-01-24 US US18/101,014 patent/US11905275B2/en active Active
-
2024
- 2024-01-02 US US18/402,493 patent/US20240150327A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123756T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
CY1120866T1 (el) | Παρεμποδιστες dna-pk | |
PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
EA201490042A1 (ru) | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak | |
EA201792619A1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы | |
MD20170016A2 (ru) | Аминопиримидиновые соединения в качестве ингибиторов JAK | |
EA201590850A1 (ru) | Трициклические конденсированные производные тиофена как ингибиторы jak | |
EA201690752A1 (ru) | Ингибиторы g12c kras | |
TR201901886T4 (tr) | DNA-PK inhibitörleri. | |
MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
MX2015017964A (es) | Inhibidores de bromodominio. | |
MX2015012005A (es) | Inhibidores de bromodominio. | |
EA201590224A1 (ru) | Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
EA201490971A1 (ru) | Производные урацила в качестве ингибиторов axl и c-met киназы | |
EA201591420A1 (ru) | Гетероарильные соединения и их применение | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
EA201792057A1 (ru) | Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы | |
EA201491227A1 (ru) | Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2 | |
EA201650003A1 (ru) | Соединённые циклоалкилом дигетероциклические производные |